drugset

drugset / Trial / NCT06855745

Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD.

NCT06855745 ↗

Phase 2 Recruiting 72 enrolled Alphyn Biologics

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Phase 2b study investigating the efficacy of zabalafin in people with mild to moderate atopic dermatitis (eczema).

Timeline

Start: 2025-03-25
Primary completion: 2025-10-30
Completion: 2025-11-28

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AB-101	Cell therapy	9.5 %	Topical

Indications